APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotheraphy-induced Nausea and Vomitting Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Chemotheraphy-induced Nausea and Vomitting Treatment Industry Growth and Trends Forecast to 2032

29 December 2025114 pages

Choose your research edition.

Industry ResearchChemotheraphy-induced Nausea and Vomitting Treatment Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

According to APO Research, the global Chemotheraphy-induced Nausea and Vomitting Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Chemotheraphy-induced Nausea and Vomitting Treatment market include Eisai, Merck & Co, GlaxoSmithKline, Tesaro, Orchid Healthcare, OPKO Health, Mylan Pharmaceuticals, Mundipharma and Heron Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Chemotheraphy-induced Nausea and Vomitting Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Chemotheraphy-induced Nausea and Vomitting Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Chemotheraphy-induced Nausea and Vomitting Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Chemotheraphy-induced Nausea and Vomitting Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Chemotheraphy-induced Nausea and Vomitting Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Chemotheraphy-induced Nausea and Vomitting Treatment Market by Company

Eisai

Merck & Co

GlaxoSmithKline

Tesaro

Orchid Healthcare

OPKO Health

Mylan Pharmaceuticals

Mundipharma

Heron Therapeutics

Helsinn

F.Hoffmann La Roche

Especificos Stendhal

Baxter Healthcare

Barr Laboratories

Aphios

Acacia Pharma

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Type

5-HT3 Inhibitors

NK1 Inhibitors

Others

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Application

Delayed Nausea and Vomitting Treatment

Acute Nausea and Vomitting Treatment

Anticipatory Nausea and Vomitting Treatment

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotheraphy-induced Nausea and Vomitting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotheraphy-induced Nausea and Vomitting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotheraphy-induced Nausea and Vomitting Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Chemotheraphy-induced Nausea and Vomitting Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2021-2026) Table 4. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2027-2032) Table 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Type (2021-2026) Table 9. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share Forecasted by Type (2027-2032) Table 11. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2021-2026) Table 24. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share Forecasted by Application (2027-2032) Table 26. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends Table 37. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Drivers Table 38. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Opportunities and Challenges Table 39. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Restraints Table 40. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Company (2021-2026) Table 42. Global Chemotheraphy-induced Nausea and Vomitting Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Chemotheraphy-induced Nausea and Vomitting Treatment Key Company Headquarters & Area Served Table 44. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company, Product Type & Application Table 45. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Chemotheraphy-induced Nausea and Vomitting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Eisai Company Information Table 49. Eisai Business Overview Table 50. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 52. Eisai Recent Development Table 53. Merck & Co Company Information Table 54. Merck & Co Business Overview Table 55. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 57. Merck & Co Recent Development Table 58. GlaxoSmithKline Company Information Table 59. GlaxoSmithKline Business Overview Table 60. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 62. GlaxoSmithKline Recent Development Table 63. Tesaro Company Information Table 64. Tesaro Business Overview Table 65. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 67. Tesaro Recent Development Table 68. Orchid Healthcare Company Information Table 69. Orchid Healthcare Business Overview Table 70. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 72. Orchid Healthcare Recent Development Table 73. OPKO Health Company Information Table 74. OPKO Health Business Overview Table 75. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 77. OPKO Health Recent Development Table 78. Mylan Pharmaceuticals Company Information Table 79. Mylan Pharmaceuticals Business Overview Table 80. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 82. Mylan Pharmaceuticals Recent Development Table 83. Mundipharma Company Information Table 84. Mundipharma Business Overview Table 85. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 87. Mundipharma Recent Development Table 88. Heron Therapeutics Company Information Table 89. Heron Therapeutics Business Overview Table 90. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 92. Heron Therapeutics Recent Development Table 93. Helsinn Company Information Table 94. Helsinn Business Overview Table 95. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 97. Helsinn Recent Development Table 98. F.Hoffmann La Roche Company Information Table 99. F.Hoffmann La Roche Business Overview Table 100. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 102. F.Hoffmann La Roche Recent Development Table 103. Especificos Stendhal Company Information Table 104. Especificos Stendhal Business Overview Table 105. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 107. Especificos Stendhal Recent Development Table 108. Baxter Healthcare Company Information Table 109. Baxter Healthcare Business Overview Table 110. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 112. Baxter Healthcare Recent Development Table 113. Barr Laboratories Company Information Table 114. Barr Laboratories Business Overview Table 115. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 117. Barr Laboratories Recent Development Table 118. Aphios Company Information Table 119. Aphios Business Overview Table 120. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 122. Aphios Recent Development Table 123. Acacia Pharma Company Information Table 124. Acacia Pharma Business Overview Table 125. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 127. Acacia Pharma Recent Development Table 128. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2026) Table 131. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share Forecast by Country (2027-2032) Table 133. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) & (US$ Million) Table 135. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2026) Table 136. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) & (US$ Million) Table 140. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2026) Table 141. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share Forecast by Country (2027-2032) Table 143. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) & (US$ Million) Table 145. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2026) Table 146. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share Forecast by Country (2027-2032) Table 148. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) & (US$ Million) Table 150. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2026) Table 151. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share Forecast by Country (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Chemotheraphy-induced Nausea and Vomitting Treatment Product Image Figure 3. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2021-2032) Figure 7. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. 5-HT3 Inhibitors Image Figure 13. Global 5-HT3 Inhibitors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. NK1 Inhibitors Image Figure 15. Global NK1 Inhibitors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Others Image Figure 17. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type 2025 VS 2032 Figure 20. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Type (2021-2032) Figure 21. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Type (2021-2032) Figure 23. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Type (2021-2032) Figure 25. Delayed Nausea and Vomitting Treatment Image Figure 26. Global Delayed Nausea and Vomitting Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Acute Nausea and Vomitting Treatment Image Figure 28. Global Acute Nausea and Vomitting Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Anticipatory Nausea and Vomitting Treatment Image Figure 30. Global Anticipatory Nausea and Vomitting Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application 2025 VS 2032 Figure 33. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2021-2032) Figure 34. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2021-2032) Figure 36. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Chemotheraphy-induced Nausea and Vomitting Treatment Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 43. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 46. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 49. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 52. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • 5-HT3 Inhibitors
  • NK1 Inhibitors
  • Others
Applications
  • Delayed Nausea and Vomitting Treatment
  • Acute Nausea and Vomitting Treatment
  • Anticipatory Nausea and Vomitting Treatment
Companies covered
  • Eisai
  • Merck & Co
  • GlaxoSmithKline
  • Tesaro
  • Orchid Healthcare
  • OPKO Health
  • Mylan Pharmaceuticals
  • Mundipharma
  • Heron Therapeutics
  • Helsinn
  • F.Hoffmann La Roche
  • Especificos Stendhal
  • Baxter Healthcare
  • Barr Laboratories
  • Aphios
  • Acacia Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
  8. 1.5.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2021-2032)
2 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 5-HT3 Inhibitors
  3. 2.1.2 NK1 Inhibitors
  4. 2.1.3 Others
  5. 2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
  6. 2.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Regions
  10. 2.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Type (2021-2026)
3 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Delayed Nausea and Vomitting Treatment
  3. 3.1.2 Acute Nausea and Vomitting Treatment
  4. 3.1.3 Anticipatory Nausea and Vomitting Treatment
  5. 3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
  6. 3.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Regions
  10. 3.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
  2. 4.2 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Drivers
  3. 4.3 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Opportunities and Challenges
  4. 4.4 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (2021-2026)
  2. 5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Key Company Headquarters & Area Served
  4. 5.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company, Product Type & Application
  5. 5.5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Chemotheraphy-induced Nausea and Vomitting Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Chemotheraphy-induced Nausea and Vomitting Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Eisai
  2. 6.1.1 Eisai Company Information
  3. 6.1.2 Eisai Business Overview
  4. 6.1.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  6. 6.1.5 Eisai Recent Developments
  7. 6.2 Merck & Co
  8. 6.2.1 Merck & Co Company Information
  9. 6.2.2 Merck & Co Business Overview
  10. 6.2.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  12. 6.2.5 Merck & Co Recent Developments
  13. 6.3 GlaxoSmithKline
  14. 6.3.1 GlaxoSmithKline Company Information
  15. 6.3.2 GlaxoSmithKline Business Overview
  16. 6.3.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  18. 6.3.5 GlaxoSmithKline Recent Developments
  19. 6.4 Tesaro
  20. 6.4.1 Tesaro Company Information
  21. 6.4.2 Tesaro Business Overview
  22. 6.4.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  24. 6.4.5 Tesaro Recent Developments
  25. 6.5 Orchid Healthcare
  26. 6.5.1 Orchid Healthcare Company Information
  27. 6.5.2 Orchid Healthcare Business Overview
  28. 6.5.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  30. 6.5.5 Orchid Healthcare Recent Developments
  31. 6.6 OPKO Health
  32. 6.6.1 OPKO Health Company Information
  33. 6.6.2 OPKO Health Business Overview
  34. 6.6.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  36. 6.6.5 OPKO Health Recent Developments
  37. 6.7 Mylan Pharmaceuticals
  38. 6.7.1 Mylan Pharmaceuticals Company Information
  39. 6.7.2 Mylan Pharmaceuticals Business Overview
  40. 6.7.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  42. 6.7.5 Mylan Pharmaceuticals Recent Developments
  43. 6.8 Mundipharma
  44. 6.8.1 Mundipharma Company Information
  45. 6.8.2 Mundipharma Business Overview
  46. 6.8.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  48. 6.8.5 Mundipharma Recent Developments
  49. 6.9 Heron Therapeutics
  50. 6.9.1 Heron Therapeutics Company Information
  51. 6.9.2 Heron Therapeutics Business Overview
  52. 6.9.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  54. 6.9.5 Heron Therapeutics Recent Developments
  55. 6.10 Helsinn
  56. 6.10.1 Helsinn Company Information
  57. 6.10.2 Helsinn Business Overview
  58. 6.10.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  60. 6.10.5 Helsinn Recent Developments
  61. 6.11 F.Hoffmann La Roche
  62. 6.11.1 F.Hoffmann La Roche Company Information
  63. 6.11.2 F.Hoffmann La Roche Business Overview
  64. 6.11.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  66. 6.11.5 F.Hoffmann La Roche Recent Developments
  67. 6.12 Especificos Stendhal
  68. 6.12.1 Especificos Stendhal Company Information
  69. 6.12.2 Especificos Stendhal Business Overview
  70. 6.12.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  72. 6.12.5 Especificos Stendhal Recent Developments
  73. 6.13 Baxter Healthcare
  74. 6.13.1 Baxter Healthcare Company Information
  75. 6.13.2 Baxter Healthcare Business Overview
  76. 6.13.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  78. 6.13.5 Baxter Healthcare Recent Developments
  79. 6.14 Barr Laboratories
  80. 6.14.1 Barr Laboratories Company Information
  81. 6.14.2 Barr Laboratories Business Overview
  82. 6.14.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  84. 6.14.5 Barr Laboratories Recent Developments
  85. 6.15 Aphios
  86. 6.15.1 Aphios Company Information
  87. 6.15.2 Aphios Business Overview
  88. 6.15.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  90. 6.15.5 Aphios Recent Developments
  91. 6.16 Acacia Pharma
  92. 6.16.1 Acacia Pharma Company Information
  93. 6.16.2 Acacia Pharma Business Overview
  94. 6.16.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  96. 6.16.5 Acacia Pharma Recent Developments
7 North America
  1. 7.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  3. 7.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  3. 10.3 South America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst